Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET(A)/ET(B) mixed antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 20, 1997, Pages 3217-3227

  Jae, Hwan Soo ^a   Winn, Martin ^a   Dixon, Douglas B ^a   Marsh, Kennan C ^a   Nguyen, Bach ^a   Opgenorth, Terry J ^a   Von Geldern, Thomas W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 METHOXYPHENYL) 4 (1,3 BENZODIOXOL 5 YL) 1 [(N,N DIBUTYLAMINO)CARBONYLMETHYL]PYRROLIDINE 3 CARBOXYLIC ACID; 2 (4 METHOXYPHENYL) 4 (1,3 BENZODIOXOL 5 YL) 1 [[(N,N DIBUTYLAMINO) CARBONYL]METHYL]PYRROLIDINE 3 CARBOXYLIC ACID; ATRASENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PYRROLIDINE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROLACTIN SECRETING CELL; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; HALF-LIFE; MALE; MODELS, CHEMICAL; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030846176     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970101g     Document Type: Article

References (18)

1. von Geldern, T. W.; Hutchins, C.; Kester, J. A.; Wu-Wong, J. R.; Chiou, W.; Dixon, D. B.; Opgenorth, T. J. Azole Endothelin Antagonists. I. A Receptor Model Explains an Unusual Structure- Activity Profile. J. Med. Chem. 1996, 39, 957-967.
2. von Geldern, T. W.; Kester, J. A.; Bal, R.; Wu-Wong, J. R.; Chiou, W.; Dixon, D. B.; Opgenorth, T. J. Azole Endothelin Antagonists. II. Structure-Activity Studies. J. Med. Chem. 1996, 39, 968- 981.
3. von Geldern, T. W.; Hoffman, D. J.; Kester, J. A.; Nellans, H. N.; Dayton, B. D.; Calzadilla, S. V.; Marsh, K. C.; Hernandez, L.; Chiou, W.; Dixon, D. B.; Wu-Wong, J. R.; Opgenorth, T. J. Azole Endothelin Antagonists. III. Using ΔlogP as a Tool to Improve Absorption. J. Med. Chem. 1996, 39, 982-991.
4. A Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722. J. Med. Chem. 1996, 39, 1039-1048.
5. A-Selective Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 473-481.
6. Tasker, A. S.; Sorensen, B. K.; Jae, H.-S.; Winn, M.; von Geldern, T. W.; Dixon, D. B.; Chiou, W. J.; Dayton, B. D.; Calzadilla, S. V.; Hernandez, L.; Marsh, K. C.; Wu-Wong, J. R.; Opgenorth, T. J. Potent and Selective non-Benzodioxole-Containing Endothelin-A Receptor Antagonists. J. Med. Chem. 1997, 40, 322- 330.
7. Opgenorth, T. J. Endothelin Receptor Antagonism. Adv. Pharmacol. 1995, 35, 1-65.
8. B-Mediated Blood Pressure Responses in Rats. J. Pharmacol. Exp. Ther. 1994, 270, 728-733. (c) (1) Ohlstein, E. H.; Nambi, P.; Lago, A.; Hay, D. W. P.; Beck, G.; Fong, K.-L.; Eddy, E. P.; Smith, P.; Ellens, H.; Elliott, J. D. Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, A Potent and Highly Bioavailable Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 609- 617. Ohlstein, E. H.; Nambi, P.; Douglas, S. A.; Edwards, R. M.; Gellai, M.; Lago, M. A.; Leber, J. D.; Cousins, R. D.; Gao, A.; Frazee, J. S.; Peishoff, C. E.; Bean, J. W.; Eggleston, D. S.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Yu, T.-L.; Louden, C.; Brooks, D. P.; Weinstock, J.; Feuerstein, G.; Poste, G.; Ruffolo, R. R., Jr.; Gleason, J. G.; Elliott, J. D. SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8052-8056. (d) Williams, D. L., Jr.; Murphy, K. L.; Nolan, N. A.; O'Brien, J. A.; Pettibone, D. J.; Kivlighn, S. D.; Krause, S. M.; Lis, E. V., Jr.; Zingaro, G. J.; Gabel, R. A.; Clayton, F. C.; Siegl, P. K. S.; Zhang, K.; Naue, J.; Vyas, K.; Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Greenlee, W. J.; Clineschmidt, B. V. Pharmacology of L-754,- 142, a Highly Potent, Orally Active, Nonpeptidyl Endothelin Antagonist. J. Pharmacol. Exp. Ther. 1995, 275, 1518-1526.
9. B-Mediated Blood Pressure Responses in Rats. J. Pharmacol. Exp. Ther. 1994, 270, 728-733. (c) (1) Ohlstein, E. H.; Nambi, P.; Lago, A.; Hay, D. W. P.; Beck, G.; Fong, K.-L.; Eddy, E. P.; Smith, P.; Ellens, H.; Elliott, J. D. Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, A Potent and Highly Bioavailable Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 609- 617. Ohlstein, E. H.; Nambi, P.; Douglas, S. A.; Edwards, R. M.; Gellai, M.; Lago, M. A.; Leber, J. D.; Cousins, R. D.; Gao, A.; Frazee, J. S.; Peishoff, C. E.; Bean, J. W.; Eggleston, D. S.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Yu, T.-L.; Louden, C.; Brooks, D. P.; Weinstock, J.; Feuerstein, G.; Poste, G.; Ruffolo, R. R., Jr.; Gleason, J. G.; Elliott, J. D. SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8052-8056. (d) Williams, D. L., Jr.; Murphy, K. L.; Nolan, N. A.; O'Brien, J. A.; Pettibone, D. J.; Kivlighn, S. D.; Krause, S. M.; Lis, E. V., Jr.; Zingaro, G. J.; Gabel, R. A.; Clayton, F. C.; Siegl, P. K. S.; Zhang, K.; Naue, J.; Vyas, K.; Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Greenlee, W. J.; Clineschmidt, B. V. Pharmacology of L-754,- 142, a Highly Potent, Orally Active, Nonpeptidyl Endothelin Antagonist. J. Pharmacol. Exp. Ther. 1995, 275, 1518-1526.
10. B-Mediated Blood Pressure Responses in Rats. J. Pharmacol. Exp. Ther. 1994, 270, 728-733. (c) (1) Ohlstein, E. H.; Nambi, P.; Lago, A.; Hay, D. W. P.; Beck, G.; Fong, K.-L.; Eddy, E. P.; Smith, P.; Ellens, H.; Elliott, J. D. Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, A Potent and Highly Bioavailable Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 609- 617. Ohlstein, E. H.; Nambi, P.; Douglas, S. A.; Edwards, R. M.; Gellai, M.; Lago, M. A.; Leber, J. D.; Cousins, R. D.; Gao, A.; Frazee, J. S.; Peishoff, C. E.; Bean, J. W.; Eggleston, D. S.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Yu, T.-L.; Louden, C.; Brooks, D. P.; Weinstock, J.; Feuerstein, G.; Poste, G.; Ruffolo, R. R., Jr.; Gleason, J. G.; Elliott, J. D. SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8052-8056. (d) Williams, D. L., Jr.; Murphy, K. L.; Nolan, N. A.; O'Brien, J. A.; Pettibone, D. J.; Kivlighn, S. D.; Krause, S. M.; Lis, E. V., Jr.; Zingaro, G. J.; Gabel, R. A.; Clayton, F. C.; Siegl, P. K. S.; Zhang, K.; Naue, J.; Vyas, K.; Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Greenlee, W. J.; Clineschmidt, B. V. Pharmacology of L-754,- 142, a Highly Potent, Orally Active, Nonpeptidyl Endothelin Antagonist. J. Pharmacol. Exp. Ther. 1995, 275, 1518-1526.
11. B-Mediated Blood Pressure Responses in Rats. J. Pharmacol. Exp. Ther. 1994, 270, 728-733. (c) (1) Ohlstein, E. H.; Nambi, P.; Lago, A.; Hay, D. W. P.; Beck, G.; Fong, K.-L.; Eddy, E. P.; Smith, P.; Ellens, H.; Elliott, J. D. Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, A Potent and Highly Bioavailable Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 609- 617. Ohlstein, E. H.; Nambi, P.; Douglas, S. A.; Edwards, R. M.; Gellai, M.; Lago, M. A.; Leber, J. D.; Cousins, R. D.; Gao, A.; Frazee, J. S.; Peishoff, C. E.; Bean, J. W.; Eggleston, D. S.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Yu, T.-L.; Louden, C.; Brooks, D. P.; Weinstock, J.; Feuerstein, G.; Poste, G.; Ruffolo, R. R., Jr.; Gleason, J. G.; Elliott, J. D. SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8052-8056. (d) Williams, D. L., Jr.; Murphy, K. L.; Nolan, N. A.; O'Brien, J. A.; Pettibone, D. J.; Kivlighn, S. D.; Krause, S. M.; Lis, E. V., Jr.; Zingaro, G. J.; Gabel, R. A.; Clayton, F. C.; Siegl, P. K. S.; Zhang, K.; Naue, J.; Vyas, K.; Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Greenlee, W. J.; Clineschmidt, B. V. Pharmacology of L-754,- 142, a Highly Potent, Orally Active, Nonpeptidyl Endothelin Antagonist. J. Pharmacol. Exp. Ther. 1995, 275, 1518-1526.
12. B-Mediated Blood Pressure Responses in Rats. J. Pharmacol. Exp. Ther. 1994, 270, 728-733. (c) (1) Ohlstein, E. H.; Nambi, P.; Lago, A.; Hay, D. W. P.; Beck, G.; Fong, K.-L.; Eddy, E. P.; Smith, P.; Ellens, H.; Elliott, J. D. Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, A Potent and Highly Bioavailable Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 609- 617. Ohlstein, E. H.; Nambi, P.; Douglas, S. A.; Edwards, R. M.; Gellai, M.; Lago, M. A.; Leber, J. D.; Cousins, R. D.; Gao, A.; Frazee, J. S.; Peishoff, C. E.; Bean, J. W.; Eggleston, D. S.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Yu, T.-L.; Louden, C.; Brooks, D. P.; Weinstock, J.; Feuerstein, G.; Poste, G.; Ruffolo, R. R., Jr.; Gleason, J. G.; Elliott, J. D. SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8052-8056. (d) Williams, D. L., Jr.; Murphy, K. L.; Nolan, N. A.; O'Brien, J. A.; Pettibone, D. J.; Kivlighn, S. D.; Krause, S. M.; Lis, E. V., Jr.; Zingaro, G. J.; Gabel, R. A.; Clayton, F. C.; Siegl, P. K. S.; Zhang, K.; Naue, J.; Vyas, K.; Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Greenlee, W. J.; Clineschmidt, B. V. Pharmacology of L-754,- 142, a Highly Potent, Orally Active, Nonpeptidyl Endothelin Antagonist. J. Pharmacol. Exp. Ther. 1995, 275, 1518-1526.
13. Wu-Wong. J. R.; Chiou, W. J.; Hoffman, D. J.; Winn, M.; von Geldern, T. W.; Opgenorth, T. J. Endothelins and Endothelin Receptor Antagonists: Binding to Plasma Proteins. Life Sci. 1996, 58, 1839-1847.
14. Roemmele, R. C.; Rapoport, H. Removal of N-Arylsulfonyl Groups from Hydroxy α-Amino Acids. J. Org. Chem. 1988, 53, 2367-2371.
15. Bunyagidi, C.; Piotrowaska, H.; Aldridge, M. Synthesis of 2,2,2- Trifluoroethanesulfonic Acid. J. Org. Chem. 1981, 46, 3335- 3336.
16. Berridge, M. J.; Downes, C. P.; Hanley, M. R. Lithium Amplifies Agonist Dependent Phosphatidylinositol Responses in Brain and Salivary Glands. Biochem. J. 1982, 206, 587-595.
17. Statistical Consultants, Inc. PCNONLIN and NONLIN84: Soft- ware for the Statistical Analysis of Nonlinear Models. Am. Stat. 1986, 40, 52.
18. Sedman, A. J.; Wagner, J. G. CSTRIP - A FORTRAN Computer Program for Obtaining Initial Polyexponential Estimates. J. Pharm. Sci. 1976, 65, 1006-1010.